Cargando…

Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs

IMPORTANCE: In many health systems, access to off-label drug use is controlled through reimbursement restrictions by health insurers, especially for expensive cancer drugs. OBJECTIVE: To determine whether evidence from randomized clinical trials is associated with reimbursement decisions for request...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herbrand, Amanda Katherina, Schmitt, Andreas M., Briel, Matthias, Ewald, Hannah, Goldkuhle, Marius, Diem, Stefan, Hoogkamer, Anouk, Joerger, Markus, Moffa, Giusi, Novak, Urban, Hemkens, Lars G., Kasenda, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926292/ https://www.ncbi.nlm.nih.gov/pubmed/33651108 http://dx.doi.org/10.1001/jamanetworkopen.2021.0380

Ejemplares similares

Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
por: Herbrand, Amanda Katherina, et al.
Publicado: (2019)

Characteristics and survival of patients with cancer with intended off-label use—a cohort study
por: Schmitt, Andreas Michael, et al.
Publicado: (2022)

Characteristics and interpretation of subgroup analyses based on tumour characteristics in randomised trials testing target-specific anticancer drugs: design of a systematic survey
por: Schandelmaier, Stefan, et al.
Publicado: (2020)

Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016
por: Ladanie, Aviv, et al.
Publicado: (2020)

Barriers and Facilitating Factors for Conducting Systematic Evidence Assessments in Academic Clinical Trials
por: McLennan, Stuart, et al.
Publicado: (2021)

Prediction of RECRUITment In randomized clinical Trials (RECRUIT-IT)—rationale and design for an international collaborative study
por: Kasenda, Benjamin, et al.
Publicado: (2020)

Off-label use information in electronic drug information resources
por: Rothgeb, Amanda, et al.
Publicado: (2022)

The reporting of studies using routinely collected health data was often insufficient
por: Hemkens, Lars G., et al.
Publicado: (2016)

Variation in Practice Patterns and Reimbursements Between Female and Male Urologists for Medicare Beneficiaries
por: Nam, Catherine S., et al.
Publicado: (2019)

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia
por: Tesar, Tomas, et al.
Publicado: (2021)

Factors Associated With Penicillin Allergy Labels in Electronic Health Records of Children in 2 Large US Pediatric Primary Care Networks
por: Taylor, Margaret G., et al.
Publicado: (2022)

Drug utilisation and off-label use of medications in anaesthesia in surgical wards of a teaching hospital
por: Patil, Amol E, et al.
Publicado: (2015)

Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
por: de Almeida Carvalho, Lelia Maria, et al.
Publicado: (2019)

Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis
por: Katsanos, Aristeidis H., et al.
Publicado: (2022)

Investigation of continuous effect modifiers in a meta-analysis on higher versus lower PEEP in patients requiring mechanical ventilation - protocol of the ICEM study
por: Kasenda, Benjamin, et al.
Publicado: (2014)

Concordance of Disclosed Hospital Prices With Total Reimbursements for Hospital-Based Care Among Commercially Insured Patients in the US
por: Horný, Michal, et al.
Publicado: (2021)

Immediate Postpartum Long-Acting Reversible Contraceptive Use Following State-Specific Changes in Hospital Medicaid Reimbursement
por: Steenland, Maria W., et al.
Publicado: (2022)

Reporting Quality of Journal Abstracts for Surgical Randomized Controlled Trials Before and After the Implementation of the CONSORT Extension for Abstracts
por: Speich, Benjamin, et al.
Publicado: (2019)

Association of the Swiss Diagnosis-Related Group Reimbursement System With Length of Stay, Mortality, and Readmission Rates in Hospitalized Adult Patients
por: Kutz, Alexander, et al.
Publicado: (2019)

The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer
por: Raphael, Michael J., et al.
Publicado: (2021)

Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study
por: Berlanga, Pablo, et al.
Publicado: (2023)

Evaluation of Planned Subgroup Analysis in Protocols of Randomized Clinical Trials
por: Taji Heravi, Ala, et al.
Publicado: (2021)

Highly effective proximate labeling in Drosophila
por: Zhang, Bo, et al.
Publicado: (2021)

When is off-label off-road?
por: de Vries, E G E, et al.
Publicado: (2019)

When is off-label off-road?
por: de Vries, E G E, et al.
Publicado: (2019)

Reimbursement of Bus Fares
Publicado: (1954)

The History of Reimbursements in Neurology
por: Lakhan, Shaheen E., et al.
Publicado: (2013)

Introduction: Pharmacy Reimbursement
por: Greenwood, Bonnie C.
Publicado: (2020)

Practices and Attitudes of Swiss Stakeholders Regarding Investigator-Initiated Clinical Trial Funding Acquisition and Cost Management
por: McLennan, Stuart, et al.
Publicado: (2021)

Meta-analysis identifies pleiotropic loci controlling phenotypic trade-offs in sorghum
por: Mural, Ravi V, et al.
Publicado: (2021)

Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics
por: Lenk, Christian, et al.
Publicado: (2009)

The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs
por: Ladanie, Aviv, et al.
Publicado: (2018)

Identifying Genetic Signatures of Natural Selection Using Pooled Population Sequencing in Picea abies
por: Chen, Jun, et al.
Publicado: (2016)

Genome-Wide Off-Target Analysis in CRISPR-Cas9 Modified Mice and Their Offspring
por: Dong, Yan, et al.
Publicado: (2019)

How is Clinical Trial Reimbursement Money Spent? South African Trial Participants’ Reported Reimbursement Spending Patterns and Perceptions of Appropriate Reimbursement Amounts
por: Milford, Cecilia, et al.
Publicado: (2021)

Effect of Wearing Glasses on Risk of Infection With SARS-CoV-2 in the Community: A Randomized Clinical Trial
por: Fretheim, Atle, et al.
Publicado: (2022)

Premature Discontinuation of Prospective Clinical Studies Approved by a Research Ethics Committee – A Comparison of Randomised and Non-Randomised Studies
por: Blümle, Anette, et al.
Publicado: (2016)

Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use—Patient Harms and Prescriber Responsibilities
por: Van Norman, Gail A.
Publicado: (2023)

Clinical Experience with Off-Label Intrathecal Administration of Selected Antibiotics in Adults: An Overview with Pharmacometric Considerations
por: Muller, Anouk E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5ksmrqujnu05hav03uf9dfapm9